Showing 20 of 58 recruiting trials for “nodal-marginal-zone-b-cell-lymphoma”
Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma
CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
Phase Ib Study of Rocbrutinib in Combination with R-CHOP in Patients with Newly Diagnosed B-cell Non-Hodgkin Lymphoma
👨⚕️ Qingqing Cai, Ph D, Sun Yat-Sen University Cancer Center📍 1 site📅 Started Apr 2024View details ↗
Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
RecruitingNCT06362148 ↗
Circulating Tumor DNA in Peripheral T-cell Lymphomas
👨⚕️ Francesco A d'Amore, MD, DMSc, Aarhus University Hospital and Aarhus University📍 1 site📅 Started Mar 2024View details ↗
PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
👨⚕️ Ramya M Ramaswami, M.D., National Cancer Institute (NCI)📍 1 site📅 Started Jun 2023View details ↗
PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma
Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
👨⚕️ Yuankai Shi, MD, Cancer Institute and Hospital, Chinese Academy of Medical Sciences📍 1 site📅 Started May 2023View details ↗
Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
👨⚕️ Jason Westin, MD, MS, FACP, M.D. Anderson Cancer Center📍 1 site📅 Started Apr 2023View details ↗
Study of SGR-1505 in Mature B-Cell Neoplasms
Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma
👨⚕️ Lapo Alinari, MD, PhD, Ohio State University Comprehensive Cancer Center📍 1 site📅 Started Mar 2023View details ↗
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →